Oxovanadium Complexes for Pain Relief via Ligand Coordination
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing pain treatments, such as NSAIDs, morphine-based drugs, and anticonvulsants, have significant limitations including analgesic ceiling effects, side effects, and are inadequate for chronic pain management, necessitating the development of drugs with new targets and lower side effects.
Innovation Solution
Development of oxovanadium metal complexes with alpha-hydroxypyranone or alpha-hydroxypyridone ligands that form a five-membered ring with a transition metal ion, offering a novel approach to pain relief by complexation with these ligands, which can be administered orally or via other routes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If non-steroidal anti-inflammatory drugs (NSAIDs) are used for pain treatment, then analgesic effect is achieved, but analgesic ceiling effect occurs and gastrointestinal side effects increase
Solution Approach 1:
The patent changes the chemical parameter from conventional NSAIDs to oxovanadium complexes with specific ligands (alpha-hydroxypyranone or alpha-hydroxypyridone), thereby altering the molecular structure and pharmacological properties to achieve pain relief without the typical NSAID side effects
Solution Approach 2:
The invention uses composite metal complexes formed by oxovanadium ions coordinated with organic ligands, creating a new class of compounds that combine the therapeutic benefits of metal complexes with the specific pharmacological properties of the organic ligands to achieve superior analgesic effects with reduced side effects
2Reliability
If morphine-based drugs are used for pain treatment, then strong analgesic effect is achieved, but side effects such as constipation, respiratory depression and addiction occur
Solution Approach 1:
The patent fundamentally changes the pharmacological parameter by using oxovanadium complexes instead of opioid compounds, achieving analgesic effects through a different mechanism of action that does not involve the opioid receptors, thereby avoiding addiction and respiratory depression
Solution Approach 2:
The oxovanadium complexes act as intermediary compounds that modulate pain pathways through non-opioid mechanisms, providing analgesia without direct activation of opioid receptors, thus avoiding the harmful effects associated with morphine-based drugs
3Reliability
If traditional analgesic drugs are used, then pain relief is achieved, but duration of action is limited and side effects prevent long-term use
Solution Approach 1:
The patent modifies the pharmacokinetic parameters by using oxovanadium complexes with specific ligands that exhibit improved metabolic stability and longer half-life, enabling sustained pain relief and potential long-term use for chronic pain conditions
Data Source
Figure 1
AI summary
A drug composition having the structure of formula I for the treatment of pain is provided. The drug can be given to an animal via oral, transdermal, rectal, intravenous, subcutaneous, sublingual or intraperitoneal administration, etc., thereby exerting an analgesic effect. The active components of the drug are convenient to prepare and easy to identify, and are structurally different from those of all other existing analgesic drugs, thus forming a novel class of effective analgesic compounds.